Research ExplorerPublicationsInhibition of thromboxane synthase activity improves gliobla...

Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.

Standard

Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. / Schmidt, Nils-Ole; Ziu, Mateo; Cargioli, Theresa; Westphal, Manfred; Giese, Alf; Black, Peter M; Carroll, Rona S.

In: TRANSL ONCOL, Vol. 3, No. 1, 1, 2010, p. 43-49.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schmidt, N-O, Ziu, M, Cargioli, T, Westphal, M, Giese, A, Black, PM & Carroll, RS 2010, 'Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.', TRANSL ONCOL, vol. 3, no. 1, 1, pp. 43-49. https://doi.org/10.1593/tlo.09238

APA

Schmidt, N-O., Ziu, M., Cargioli, T., Westphal, M., Giese, A., Black, P. M., & Carroll, R. S. (2010). Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. TRANSL ONCOL, 3(1), 43-49. [1]. https://doi.org/10.1593/tlo.09238

Vancouver

Schmidt N-O, Ziu M, Cargioli T, Westphal M, Giese A, Black PM et al. Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy. TRANSL ONCOL. 2010;3(1):43-49. 1. https://doi.org/10.1593/tlo.09238

Bibtex

@article{de445c680e064b53827d1f4121c9842a,
title = "Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.",
abstract = "Thromboxane synthase (TXSA), an enzyme of the arachidonic acid metabolism, is upregulated in human glial tumors and is involved in glioma progression. Here, we analyzed the in vitro and in vivo effects of pharmacological inhibition of TXSA activity on human glioblastoma cells. Furegrelate, a specific inhibitor of TXSA, significantly inhibited tumor growth in an orthotopic glioblastoma model by inducing proapoptotic, antiproliferative, and antiangiogenic effects. Inhibition of TXSA induced a proapoptotic disposition of glioma cells and increased the sensitivity to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea, significantly prolonging the survival time of intracerebral glioma-bearing mice. Our data demonstrate that the targeted inhibition of TXSA activity improves the efficiency of conventional alkylation chemotherapy in vivo. Our study supports the role of TXSA activity for the progression of malignant glioma and the potential utility of its therapeutic modulation for glioma treatment.",
author = "Nils-Ole Schmidt and Mateo Ziu and Theresa Cargioli and Manfred Westphal and Alf Giese and Black, {Peter M} and Carroll, {Rona S}",
year = "2010",
doi = "10.1593/tlo.09238",
language = "Deutsch",
volume = "3",
pages = "43--49",
journal = "TRANSL ONCOL",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "1",

}

RIS

TY - JOUR

T1 - Inhibition of thromboxane synthase activity improves glioblastoma response to alkylation chemotherapy.

AU - Schmidt, Nils-Ole

AU - Ziu, Mateo

AU - Cargioli, Theresa

AU - Westphal, Manfred

AU - Giese, Alf

AU - Black, Peter M

AU - Carroll, Rona S

PY - 2010

Y1 - 2010

N2 - Thromboxane synthase (TXSA), an enzyme of the arachidonic acid metabolism, is upregulated in human glial tumors and is involved in glioma progression. Here, we analyzed the in vitro and in vivo effects of pharmacological inhibition of TXSA activity on human glioblastoma cells. Furegrelate, a specific inhibitor of TXSA, significantly inhibited tumor growth in an orthotopic glioblastoma model by inducing proapoptotic, antiproliferative, and antiangiogenic effects. Inhibition of TXSA induced a proapoptotic disposition of glioma cells and increased the sensitivity to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea, significantly prolonging the survival time of intracerebral glioma-bearing mice. Our data demonstrate that the targeted inhibition of TXSA activity improves the efficiency of conventional alkylation chemotherapy in vivo. Our study supports the role of TXSA activity for the progression of malignant glioma and the potential utility of its therapeutic modulation for glioma treatment.

AB - Thromboxane synthase (TXSA), an enzyme of the arachidonic acid metabolism, is upregulated in human glial tumors and is involved in glioma progression. Here, we analyzed the in vitro and in vivo effects of pharmacological inhibition of TXSA activity on human glioblastoma cells. Furegrelate, a specific inhibitor of TXSA, significantly inhibited tumor growth in an orthotopic glioblastoma model by inducing proapoptotic, antiproliferative, and antiangiogenic effects. Inhibition of TXSA induced a proapoptotic disposition of glioma cells and increased the sensitivity to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea, significantly prolonging the survival time of intracerebral glioma-bearing mice. Our data demonstrate that the targeted inhibition of TXSA activity improves the efficiency of conventional alkylation chemotherapy in vivo. Our study supports the role of TXSA activity for the progression of malignant glioma and the potential utility of its therapeutic modulation for glioma treatment.

U2 - 10.1593/tlo.09238

DO - 10.1593/tlo.09238

M3 - SCORING: Zeitschriftenaufsatz

VL - 3

SP - 43

EP - 49

JO - TRANSL ONCOL

JF - TRANSL ONCOL

SN - 1936-5233

IS - 1

M1 - 1

ER -